We are comparing Array BioPharma Inc. (NASDAQ:ARRY) and Voyager Therapeutics Inc. (NASDAQ:VYGR) on their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Array BioPharma Inc.	180.09M	26.71	111.47M	-0.65	0.00
Voyager Therapeutics Inc.	11.96M	28.97	77.59M	-2.46	0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Array BioPharma Inc. and Voyager Therapeutics Inc.

Profitability

Table 2 hightlights the net margins, return on equity and return on assets of the two companies.

	Net Margins	Return on Equity	Return on Assets
Array BioPharma Inc.	-61.90%	-56.7%	-28.2%
Voyager Therapeutics Inc.	-648.75%	-81.7%	-37.3%

Liquidity

The current Quick Ratio of Array BioPharma Inc. is 5.6 while its Current Ratio is 5.6. Meanwhile, Voyager Therapeutics Inc. has a Current Ratio of 6.1 while its Quick Ratio is 6.1. Voyager Therapeutics Inc. is better positioned to pay off its short-term and long-term debts than Array BioPharma Inc.

Analyst Ratings

The Ratings and Recommendations for Array BioPharma Inc. and Voyager Therapeutics Inc. are featured in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Array BioPharma Inc.	0	1	2	2.67
Voyager Therapeutics Inc.	0	0	0	0.00

Array BioPharma Inc.’s upside potential currently stands at 13.43% and an $25 consensus target price.

Insider & Institutional Ownership

The shares of both Array BioPharma Inc. and Voyager Therapeutics Inc. are owned by institutional investors at 98.1% and 90.4% respectively. Array BioPharma Inc.’s share owned by insiders are 0.4%. Comparatively, 0.3% are Voyager Therapeutics Inc.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Array BioPharma Inc.	-3.14%	-9.82%	7.15%	-13.46%	42.87%	20.55%
Voyager Therapeutics Inc.	-3.16%	-21.09%	-42.02%	-46.9%	-19.65%	-33.49%

For the past year Array BioPharma Inc. had bullish trend while Voyager Therapeutics Inc. had bearish trend.

Summary

On 8 of the 11 factors Array BioPharma Inc. beats Voyager Therapeutics Inc.

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The companyÂ’s drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus. Its drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer. In addition, the company is developing ARRY-797, a p38 inhibitor, which is in Phase II clinical trials for Lamin A/C-related dilated cardiomyopathy; Motolimod/VTX-2337, a Toll-like receptor that is under Phase II clinical studies for cancer; and Prexasertib/LY2606368, a CHK-1 inhibitor, which is in Phase II clinical studies for cancer, as well as ARRY-382, a CSF1R inhibitor that is under Phase I/II clinical trial to treat cancer. Further, it is developing GDC-0575, a CHK-1 inhibitor that is in Phase Ib clinical trial for the treatment of cancer; LOXO-292, a RET inhibitor, which is under Phase I clinical trials to treat cancer; and LOXO-195, a NTRK inhibitor that is under Phase I clinical trials to treat cancer. Array BioPharma Inc. has a collaboration agreement with Amgen, Asahi Kasei Pharma Corporation, Loxo Oncology, and Mirati Therapeutics, Inc. The company was founded in 1998 and is headquartered in Boulder, Colorado.

Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. The companyÂ’s lead clinical candidate is the VY-AADC01, which is in Phase Ib clinical trial for the treatment of advanced Parkinson's disease. Its preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis; VY-HTT01 for HuntingtonÂ’s disease; VY-FXN01 for Friedreich's ataxia; VY-TAU01, AlzheimerÂ’s disease; and VY-NAV01 for severe chronic pain. The company has strategic collaboration agreements with Genzyme Corporation and the University of Massachusetts. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.